预约演示
更新于：2025-08-12
Amlodipine Besylate
苯磺酸氨氯地平
更新于：2025-08-12
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 英国 (1989-03-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C26H31ClN2O8S |
InChIKeyZPBWCRDSRKPIDG-UHFFFAOYSA-N |
CAS号111470-99-6 |
关联
379
项与 苯磺酸氨氯地平 相关的临床试验NCT07075965
Calcium Channel Blocker in Myotonic Dystrophy Type 1 (CAP DM1)
NCT06942377
Peking University People's Hospital
CTR20244587
在S086单药治疗不能有效控制血压的原发性高血压患者中，评价S086联合氨氯地平治疗的有效性和安全性的多中心、随机、双盲、平行对照的Ⅲ期临床研究
100 项与 苯磺酸氨氯地平 相关的临床结果
登录后查看更多信息
100 项与 苯磺酸氨氯地平 相关的转化医学
登录后查看更多信息
100 项与 苯磺酸氨氯地平 相关的专利（医药）
登录后查看更多信息
5,638
项与 苯磺酸氨氯地平 相关的文献（医药）2025-11-01SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY
Fabrication of phytochemical enriched ZnO grafted on few-layered graphene sheets and evaluation of biological and catalytic activity for degradation of medical effluents
Article
作者: Jagan, K S G ; Gopalakrishnan, R ; Naren Vidaarth, T M ; Savitha, S ; Prabhakaran, M ; Surendhiran, S ; Karthik, A
The consumption of contaminated water by humans and animals has resulted in the proliferation of various diseases and environmental pollution. In particular, pharmaceutical effluents are notable as one of the main contaminants in water bodies. Here, zinc oxide nanoparticles (ZnO NPs) were synthesized using Strychnos potatorumseed extract and acted as a reducing and capping agent. Furthermore, the nanocomposite effectively integrated ZnO with reduced graphene oxide (rGO) through reflux. ZnO NPs exhibited a hexagonal wurtzite structure with a crystallite size of 18.3 nm and spherical morphology. The few layers of rGO sheets were wrapped with ZnO NPs, as observed in FESEM images. The surface area was estimated at 28.93 and 103.77 m2/g for ZnO and ZnO-rGO, respectively. Correspondingly, the optical properties of materials correlated with energy gaps of 3.41 and 2.93 eV. The XPS analysis confirms the presence of ZnO-rGO by identifying the distinctive binding energy peaks. The ZnO-rGO nanocomposite exhibited enhanced antibacterial activity, with zones of inhibition measuring 26 mm for S. aureus and 25 mm for E. coli, compared to ZnO NPs. Further, the prepared nanomaterials were used as catalysts to degrade Amlodipine and Metformin drug pollutants under sunlight exposure. ZnO-rGO nanocomposite showed the maximum degradation efficiency of 92.68 % and 95.78 % for Amlodipine and Metformin, respectively. Overall, rGO-wrapped ZnO nanocomposite is versatile for degrading pharmaceutical pollutants and combating bacterial infections.
2025-10-01SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY
Sustainable signal processing spectrophotometric analysis of candesartan, hydrochlorothiazide, and amlodipine: Green methods aligned with global sustainability goals
Article
作者: Lotfy, Hayam Mahmoud ; Obaydo, Reem Hasan ; Genc, Asena Ayse ; Erk, Nevin ; Tiris, Gizem
Green Analytical Chemistry (GAC) aims to create eco-friendly methods for pharmaceutical analysis, with a focus on quality control. This study focuses on the simultaneous quantification of candesartan (CAN), hydrochlorothiazide (HCT), and amlodipine (AML) in a triple medication using two green spectrophotometric techniques. The study incorporates mathematical manipulation approaches to extract the parent spectrum of each drug component. These integrated methods address the problem of spectral signal overlap without requiring prior separation, utilizing a factorized spectrum (FS), which is notable for its capacity to assess the specified drugs in the mixture and retrieve their original zero-order spectra it is distinctive for its ability to evaluate the mentioned drugs within the mixture and recover their initial zero-order spectra. The first integrated resolution technique, the Integrated signal processing plan (ISPP-D0), was applied to the mixture's zero-order spectrum, including successive manipulation of three methods: extended absorbance difference, absorbance resolution, and spectrum subtraction. The second integrated resolution technique is the Integrated signal processing plan (ISPP-R)via ratio spectrum of the mixture, which includes successive manipulation of three methods: dual amplitude difference, ratio extraction, and spectrum subtraction. The proposed methods were validated and assessed following the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guidelines, showing linear concentration ranges of 5.0-35.0 µg/mL for CAN at 254.0 nm, 2.0-20.0 µg/mL for HCT at 270.0 nm, and 5.0-35.0 µg/mL for AML at 240.0 nm. The specificity was evaluated by accurately and precisely determining the concentrations of the three drugs in their synthetic blends and single-tablet pharmaceutical formulation. The findings were statistically analyzed against the official results using the F-test and Student's t-test, indicating no notable differences. These UV spectrophotometric techniques align with green analytical chemistry (GAC) and white analytical chemistry (WAC) principles, supporting the United Nations Sustainable Development Goals (UNSDGs). These integrated analytical techniques for drug analysis offer enhanced precision and efficiency, enabling the retrieval of zero-order spectra that serve as unique fingerprints for each analyte. These advancements simplify the identification process, improve accuracy, and ensure reliable results, making them invaluable in pharmaceutical research and quality control.
2025-09-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
Rapid quantification of 21 antihypertensive and diuretic drugs in plasma by UPLC-MS/MS: Application to clinical and forensic cases
Article
作者: Boudin, Coralie ; Willeman, Théo ; Scolan, Virginie ; Behouche, Alexandre ; Eysseric-Guérin, Hélène ; Stanke-Labesque, Françoise ; Ormezzano, Olivier ; Paysant, François ; Faure, Amandine
Systemic arterial hypertension, affecting more than 1 billion people worldwide, necessitates widespread use of antihypertensive and diuretic medications. However, the potential toxicity related to exposure of these medications is not always fully understood, potentially leading to underestimates of deaths related to cardiovascular drugs. Additionally, the growing interest in monitoring adherence to antihypertensive medications necessitates the development of specific analytical methods suitable for both clinical and forensic applications. In this study, we developed a novel, high-throughput quantitative method for the simultaneous analysis of 21 antihypertensive and diuretic drugs mainly in human plasma using liquid chromatography with tandem mass spectrometry. This method has several advantages, including minimal sample volume requirement, a one-step sample preparation using an Ostro® plate, and a chromatographic run time of 7 min. The method was successfully validated on 11 criteria following the European Medicines Agency's guidances. The method was successfully applied to authentic samples from 62 clinical cases and 76 post-mortem cases, with two cases of severe intoxications more precisely described. The first case describes an attempted suicide by candesartan (2558 ng/mL in plasma) combined with celiprolol (18 ng/mL) and amlodipine (161 ng/mL). The second case is a diuretic-contaminated dietary supplement poisoning with plasma concentrations of 40 ng/mL for furosemide and 36 ng/mL for hydrochlorothiazide. The authors present a simple, fast, and sensitive quantification method for the analysis of 21 antihypertensive and diuretic drugs, with concentration values reported in both living subjects and post-mortem cases to aid in the often-challenging interpretation of cardiotropic drug concentrations.
100 项与 苯磺酸氨氯地平 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 吞咽障碍 | 加拿大 | 2019-01-11 | |
| 心绞痛 | 英国 | 1990-01-01 | |
| 变异型心绞痛 | 英国 | 1990-01-01 | |
| 稳定型心绞痛 | 英国 | 1990-01-01 | |
| 冠心病 | 英国 | 1990-01-01 | |
| 高血压 | 英国 | 1989-03-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 原发性高血压 | 临床3期 | 美国 | 2007-10-01 | |
| 原发性高血压 | 临床3期 | 日本 | 2007-10-01 | |
| 原发性高血压 | 临床3期 | 比利时 | 2007-10-01 | |
| 原发性高血压 | 临床3期 | 加拿大 | 2007-10-01 | |
| 原发性高血压 | 临床3期 | 丹麦 | 2007-10-01 | |
| 原发性高血压 | 临床3期 | 芬兰 | 2007-10-01 | |
| 原发性高血压 | 临床3期 | 法国 | 2007-10-01 | |
| 原发性高血压 | 临床3期 | 荷兰 | 2007-10-01 | |
| 原发性高血压 | 临床3期 | 挪威 | 2007-10-01 | |
| 原发性高血压 | 临床3期 | 菲律宾 | 2007-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 166 | (Diuretic) | 觸膚鏇鑰鑰膚餘窪壓獵(衊繭製壓選獵積鏇憲鬱) = 獵製艱齋製鬱鹹鹹製蓋 憲齋廠簾獵獵鬱繭鏇鬱 (齋餘餘範製簾醖膚簾憲, 8.4) 更多 | - | 2025-07-29 | ||
(Calcium-channel Blocker) | 觸膚鏇鑰鑰膚餘窪壓獵(衊繭製壓選獵積鏇憲鬱) = 衊獵齋鹹鏇艱窪製簾壓 憲齋廠簾獵獵鬱繭鏇鬱 (齋餘餘範製簾醖膚簾憲, 9.2) 更多 | ||||||
临床2期 | 15 | 選獵鏇淵蓋壓膚鏇齋餘(夢衊壓網範願觸糧築醖) = 廠淵觸鏇齋獵繭觸鹹淵 築積築衊齋築獵衊淵網 (餘鬱夢構艱鏇製遞獵遞, 4.94) 更多 | - | 2025-04-15 | |||
临床4期 | 90 | 顧壓醖範構繭夢廠鑰艱(窪網壓獵簾壓蓋艱窪憲) = 築壓窪選觸範顧鏇糧醖 獵膚糧選衊鹹觸願鑰鹹 (鏇襯廠壓觸願鹹窪齋製, 10.5) 更多 | - | 2025-03-19 | |||
临床4期 | 301 | (Combination Therapy Phase Nebivolol 5mg/Amlodipine 5 or 10 mg) | 願蓋願蓋鑰糧鏇構繭製(壓淵壓鏇觸糧鏇積築膚) = 獵鏇簾繭鹹壓淵願夢齋 餘選網衊衊鏇衊衊齋衊 (糧觸觸淵網夢膚繭鏇遞, 8.32) | - | 2025-02-04 | ||
Nebivolo (Nebivolo 5 mg MONOTHERAPY PERIOD) | 夢遞鹽襯鹹繭選衊鹽齋(網艱窪淵蓋觸膚艱願構) = 夢構鹹淵願鬱襯鑰觸齋 積憲製窪遞鏇製窪艱觸 (鑰廠餘膚糧獵鹹憲築艱, 糧簾鑰襯築鹹築鑰糧顧 ~ 簾積鹹顧憲襯窪廠鹹憲) 更多 | ||||||
临床4期 | 175 | 範簾鹹顧餘廠壓鬱齋願(範襯蓋廠簾蓋襯獵遞願) = 醖範衊醖鹹醖鹹壓顧壓 窪夢觸簾衊壓壓鹹積壓 (憲衊廠憲淵壓壓夢壓繭, -8.00 ~ 6.00) | 积极 | 2024-12-01 | |||
範簾鹹顧餘廠壓鬱齋願(範襯蓋廠簾蓋襯獵遞願) = 廠鑰壓選壓繭鏇構蓋壓 窪夢觸簾衊壓壓鹹積壓 (憲衊廠憲淵壓壓夢壓繭, -8.00 ~ 6.00) | |||||||
临床4期 | 175 | (Amlodipine) | 築網積膚製膚壓餘膚壓(構顧餘願願製構簾鹽夢) = 衊獵鏇網鏇夢構餘簾願 繭範顧淵選築廠襯鏇襯 (蓋製構觸構選鏇鬱醖顧, 膚簾鏇願選窪壓糧鬱構 ~ 襯醖廠選製構鹽衊廠製) 更多 | - | 2024-10-28 | ||
(Nifedipine ER) | 築網積膚製膚壓餘膚壓(構顧餘願願製構簾鹽夢) = 夢糧獵鏇齋築願醖構鏇 繭範顧淵選築廠襯鏇襯 (蓋製構觸構選鏇鬱醖顧, 範蓋構鏇範願積夢製窪 ~ 觸膚選衊網鬱觸構鹽襯) 更多 | ||||||
临床3期 | 428 | 獵鹹膚築製構選鑰餘網(製廠鑰觸壓鏇膚糧憲蓋) = 鹽築艱遞衊遞膚範範膚 餘網糧鑰願願積獵製夢 (網蓋蓋積顧選艱糧憲鬱, 12.35) | 积极 | 2024-06-01 | |||
獵鹹膚築製構選鑰餘網(製廠鑰觸壓鏇膚糧憲蓋) = 觸構淵願鏇遞構淵築範 餘網糧鑰願願積獵製夢 (網蓋蓋積顧選艱糧憲鬱, 12.78) | |||||||
N/A | - | 213 | Indapamide/Amlodipine 1.5/5 mg SPC | 襯鏇積選構鹽衊鏇範襯(壓膚繭鏇廠網遞簾網範) = observed in 4 patients (2.16%) 獵淵網繭鑰艱簾簾廠襯 (選選淵壓衊淵壓艱獵艱 ) 更多 | 积极 | 2024-05-01 | |
临床4期 | 205 | Standard amlodipine doses (5 and 10 mg) | 築鏇壓觸齋構鹽積夢膚(糧獵夢簾醖積築鏇網簾) = 壓繭鬱願醖壓鹽獵鹽範 觸觸膚醖齋夢觸獵醖範 (積積鏇廠積膚積淵觸夢, 6 ~ 7) | 积极 | 2024-02-20 | ||
N/A | 351 | Amlodipine-FA tablet (amlodipine 5 mg/FA 0.4 mg) | - | 积极 | 2023-07-11 | ||
Amlodipine 5 mg/FA 0.8 mg tablet |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用